Balchem vs Innospec
Innospec reported revenue of $1.8 billion in fiscal 2025, 1.7 times Balchem's $1.0 billion in fiscal 2025. Balchem's revenue grew 8.8% in its latest year, and Innospec's fell 3.6%. Balchem had an operating margin of 20.2%, against 7.3% at Innospec. Free cash flow was $173 million at Balchem and $88 million at Innospec.
Side by side
| Balchem | Innospec | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $1.0B | $1.8B |
| Revenue growth | 8.8% | −3.6% |
| Revenue growth a year, last 5 years | 8.1% | 8.3% |
| Gross margin | 35.7% | 27.7% |
| Operating margin | 20.2% | 7.3% |
| Net margin | 14.9% | 6.6% |
| Free cash flow | $173M | $88M |
| Free cash flow margin | 16.7% | 5.0% |
| Return on capital | — | 11.1% |
| Net debt to EBITDA | — | −1.7x |
| Dividends and buybacks | $136M | $66M |
| Change in diluted share count | −0.3% | −0.5% |
| Last close | $170.62 | $99.18 |
| P/E at the last close | 32.1× | 20.2× |
| Insider trades, last 12 months | sold $2.3 million | bought $25,191, sold $398,854 |
| Piotroski F-score | — | 6 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
BalchemInnospec
Operating margin
Percent of revenue
BalchemInnospec
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
BalchemInnospec